Kornimate/medical-research-clean huggingface dataset:
pilonidal excision versus endoscopic surgery

Conditions: Pilonidal Sinus

Summary: compare clinical outcomes of endoscopic pilonidal sinus treatment (epsit) with excision treatment with a randomised clinical trial.

primary outcome: complication rate secondary outcomes: quality of life, recurrence rate, length of stay, post operative pain (nrs), return to work time, time to complete wound healing, resource use. allocation ratio 2:1

Eligibility criteria:
inclusion criteria: * asa i or ii * pilonidal disease \<3 previous treatments * previous incision and drainage allowed * over 16 years exclusion criteria: * co-morbidity \>asa ii * unable to consent themselves * under 16 years * vulnerable adults

Keywords: endoscopic pilonidal sinus treatment (epsit)
effects of perioperative immunonutrition in patients with head and neck cancer

Conditions: Head and Neck Cancer; Nutrition, Healthy

Summary: a prospective randomized controlled study compared the effects of perioperative immunonutrition and standard enteral nutrition (en) on postoperative short-term outcomes of patients with head and neck (hnc). five days before surgery and the postoperative day 10, immunonutrition support was given to the intervention group (n=17), and standard en support was given to the control group (n=17). body analyses were made, food consumption records were taken, nrs-2002 and quality of life scales were applied, and biochemical parameters were recorded.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx who will undergo surgery, * who agree to receive standard en or immunonutrition before surgery, * those between the ages of 18-75, * those with normal hematopoietic (absolute neutrophil count \>1.8x109/l, hemoglobin level ≥9 g/dl) hepatic and renal function exclusion criteria: * patients receiving neoadjuvant chemotherapy or radiotherapy to the head and neck region; * received en support before the study * have an active infection, any autoimmune, renal or hepatic disease, malabsorption, type 1 diabetes or mental illness * taking vitamin-mineral supplements and immunosuppressive treatment, * morbidly obese (bmi ≥40 kg/m2), hiv positive, pregnant and breastfeeding individuals

Keywords: head and neck cancer immunonutrition enteral nutrition perioperative nutrition nutritional counseling
study of the effectiveness of three different doses of opc-34712 in the treatment of adults with acute schizophrenia

Conditions: Acute Schizophrenia

Summary: the purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of opc-34712 with placebo in the treatment of acute schizophrenia in adults.

schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. the first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as hyperprolactinemia and weight gain. in addition, the safety of these drugs vary considerably.

Eligibility criteria:
inclusion criteria: 1. male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by the diagnostic and statistical manual of mental disorders (dsm-iv-tr) criteria 2. subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia 3. subjects experiencing an acute exacerbation of psychotic symptoms 4. other protocol specific inclusion criteria may apply exclusion criteria: 1. females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug 2. subjects with a current dsm-iv-tr axis i diagnosis of: * schizoaffective disorder * major depressive disorder (mdd) * bipolar disorder * delirium, dementia, amnestic or other cognitive disorder * borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder 3. subjects presenting with a first episode of schizophrenia 4. other protocol specific exclusion criteria may apply
a phase i study of the safety of proleukin (aldesleukin) in combination with ganciclovir and antiretroviral therapy in hiv seropositive patients with cytomegalovirus (cmv) retinitis

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: to determine the mtd and dose-limiting toxicities of a regimen of therapeutic ganciclovir, antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; proleukin) as an immune adjuvant in hiv-seropositive patients. to investigate the effect of increasing doses of proleukin on the time to progression of cmv retinitis in patients being treated with therapeutic ganciclovir and antiretroviral therapy. to evaluate the incidence and level of anti-il-2 antibody formation to subcutaneously administered proleukin in this patient population.

patients will receive subcutaneous proleukin in combination with ganciclovir and antiretroviral therapy, and the mtd will be determined.

Eligibility criteria:
inclusion criteria patients must have: documented hiv seropositivity. prior medication: required: * fda-approved antiretroviral therapy for at least 2 months prior to study entry. allowed: * prior g-csf.

Keywords: retinitis interleukin-2 ganciclovir drug therapy, combination acquired immunodeficiency syndrome antiviral agents
an open-label study investigating the effects of early skin barrier protection on the development of atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.

all neonates will be treated with cetaphil cream starting within 1 week of birth. all neonates enrolled will have an increased risk of developing atopic dermatitis because they have a family history of either asthma, hay fever, or atopic dermatitis. these neonates will then be followed for 2 years for the signs and symptoms of atopic dermatitis.

Eligibility criteria:
inclusion criteria: * at least one parent diagnosed with atopic dermatitis * one parent or sibling with hayfever or asthma exclusion criteria: * newborns with dermatitis at birth * newborns born greater than four weeks prematurely * newborns with medical problems necessitating prolonged hospitalization * newborns diagnosed with any immune deficiency syndrome

Keywords: atopic dermatitis prevention skin barrier
spot vision screening

Conditions: Vision Disorders

Summary: the purpose of this protocol is to determine if the welch-allyn spot vision screener (spot) is effective at detecting various risk factors for poor vision in developmentally delayed children. these children have a higher percentage of vision disorders than the average population. the spot screen itself takes about six seconds to complete. it produces a photograph of the eye and a print out with amount of hyperopia, myopia, astigmatism and pupil size. the subject will have three spot screens around the time of their standard of care eye exam. the data obtained from the three spot screens will be compared among themselves for accuracy and to the findings of the clinical eye exam.


Eligibility criteria:
inclusion criteria: child over 4 months of age social, behavioral, physical, or other handicap unable to complete age-appropriate vision screening exclusion criteria: glaucoma post intraocular surgery microphthalmia other serious eye disorder inability to complete spot screener
the influence of personality on pulmonary fibrosis and sarcoidosis

Conditions: Sarcoidosis; Pulmonary Fibrosis

Summary: a number of studies have shown that the quality of life of two common interstitial lung diseases (ild), sarcoidosis and pulmonary fibrosis patients, is impaired and that fatigue is a substantial problem for those patients. furthermore, breathlessness is an additional major problem in pulmonary fibrosis. in the field of cardiovascular disease and breast cancer, personality factors have shown to play a role in patient's morbidity, mortality, quality of life, fatigue, depressive symptoms, and one study showed a predictive role of personality factors in health care consumption. no studies examining personality factors have been performed in sarcoidosis or pulmonary fibrosis. therefore, the aim of the present study is to examine the role of personality factors as predictors of fatigue, quality of life, prognosis, and health care consumption in sarcoidosis and pulmonary fibrosis. in this study a number of possible moderators, such as social support, will also be examined, aiming to get a full picture of the relationship between the various factors examined. known and new sarcoidosis and pulmonary fibrosis patients (inclusion period 1 year) of ild care team of the outpatient clinic of the department of respiratory medicine of the university hospital maastricht will be asked to participate through completing questionnaires at baseline and every six months for 18 months, and allowing the researchers access to their medical records for the purpose of this study.


Eligibility criteria:
inclusion criteria: * patients have to be diagnosed with sarcoidosis based on consistent clinical features and bal fluid analysis results, according to the wasog guidelines. * the diagnosis ipf will be made based on the ats guidelines exclusion criteria: * poor expression in the dutch language * relevant co morbidity such as a malignancy, dementia, and a history of psychiatric illness

Keywords: personality fatigue quality of life health care consumption
effect of propofol-dexmedetomidine on cerebral oxygenation and metabolism during brain tumor resection

Conditions: Brain Tumor; Surgery

Summary: despite theoretical benefits of intravenous agents, volatile agents remain popular. in a study comparing desflurane, isoflurane, and sevoflurane in a porcine model of intracranial hypertension, at equipotent doses and normocapnia, cerebral blood flow (cbf) and intra-cranial pressure (icp) were least with sevoflurane. propofol is the most commonly used intravenous anesthetic. it has many theoretical advantages by reducing cerebral blood volume (cbv) and icp and preserving both autoregulation and vascular reactivity. neurosurgical patients anaesthetized with propofol were found to have lower icp and higher cpp than those anaesthetized with isoflurane or sevoflurane. the well known pharmacodynamic advantages of intravenous anesthetics may give this group of drugs superior cerebral effects when compared with inhalation anesthetics.

the aim of this study is to evaluate the cerebral haemodaynamics and global cerebral oxygenation as well as the systemic haemodaynamic changes using dexmedetomidine, propofol and fentanyl as total intravenous anaesthestics (tiva) in comparison with sevoflurane - fentanyl anesthesia in brain tumor resection. indicators of global cerebral oxygenation and haemodynamics will be calculated using jugular bulb and peripheral arterial blood sampling. * induction: propofol, 1.5 - 2 mg/kg. * muscle relaxants: atracurium, 0.5 mg/kg with induction and 0.1 mg/kg/20min. for maintenance. * cannulation: arterial cannula: under complete aseptic conditions 20g cannula was inserted into the radial artery of non dominant hand after performing modified allen's test and local infiltration of 0.5ml xylocaine 2%. central venous catheter: a suitable central venous catheter will be inserted into rt subclavian vein under complete aseptic technique, its correct position will be confirmed with chest x-ray. jugular bulb catheterization: under strict sterile technique the right internal jugular vein will be cannulated in a retrograde technique with confirmation of the catheter tip position using x-ray (c- arm). puncture site will be at the level of cricoid cartilage behind the anterior border of the sternocleido-mastoid muscle.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status iii or iv. * patients scheduled for elective brain tumor resection exclusion criteria: * morbid obese patients. * severe or uncompensated cardiovascular diseases. * severe or uncompensated renal diseases. * severe or uncompensated hepatic diseases. * severe or uncompensated endocrinal diseases. * pregnancy. * postpartum or lactating females. * allergy to one of the agents used. * severely altered consciousness level. * sitting position during surgery. * prone position during surgery,
validation of a high-risk versus low-risk referral model in suspected acute coronary syndrome

Conditions: Acute Myocardial Infarction

Summary: in emergency departments patients admitted with chest pain may suffer from non-significant to lifethreatening conditions. the aim of the present study is to develop and validate a referral model in chest pain patients which divide the patients with non- significant ecg changes into high risk and low risk groups for acute coronary syndrome.


Eligibility criteria:
inclusion criteria: * more than 15 years old exclusion criteria: * patients with st-elevations in ecg
the metabolic effects of consuming sugar-sweetened beverages for two weeks

Conditions: Metabolic Syndrome; Insulin Resistance; Dyslipidemia

Summary: the purpose of this study is to examine the effects of consumption of sugar-sweetened beverages on blood triglycerides and cholesterol, cholesterol concentrations, and the body's sensitivity to insulin.

the study is designed as a prospective, blinded diet intervention study during which the participants consume either fructose- or hfcs-sweetened beverages (providing 10%, 17.5% or 25% of energy) with meals. in addition, there will be two control groups, with one group consuming 0% sugar beverages sweetened with sucralose and the other consuming glucose-sweetened beverages at 25% of energy requirement. experimental procedures, including 24-hour serial blood sampling, post-heparin infusions, gluteal biopsies, magnetic resonance imaging of the liver and the abdomen, and oral glucose tolerance and disposal tests, are performed during baseline and at the end of a 2-week intervention period at the uc davis clinical and translational science center (ctsc) clinical research center (ccrc). during the inpatient periods, subjects are served energy balanced diets. the diets provide 15% of energy as protein, 30% as fat, and 55% as carbohydrate. during baseline testing, the carbohydrate content consists primarily of complex carbohydrate (\>97%). during intervention the 55% carbohydrate will consist of 10% sugar/45% complex, 17.5% sugar/37.5% complex, or 25% sugar/30% complex depending on the diet group to which the subject is assigned. during the outpatient intervention periods, the subjects reside at home and are provided with fructose- or hfcs -sweetened beverages that are consumed with each meal along with a self-selected ad libitum (usual) diet.

Eligibility criteria:
inclusion criteria: * body mass index between 18-35 * self report of stable body weight during the past six months exclusion criteria: * diabetes mellitus * evidence of liver disorder * evidence of kidney disorder * evidence of thyroid disorder * systolic blood pressure consistently over 160mmhg or diastolic blood pressure over 900mmhg * triglycerides \> 400mg/dl * ldl-c \> 240mg/dl * hemoglobin \< 8.5 g/dl * current, prior (within 2 months), or anticipated use of any hypolipidemic or anti-diabetic agents * use of selective serotonin reuptake inhibitors and anti-hypertensive medications * any other condition that, in the opinion of the investigators, would put subject at risk * strenuous exerciser * pregnant or lactating women * smoker * diet exclusions: food allergies, special dietary restrictions, habitual ingest of \>2 alcoholic beverages/day

Keywords: sugar fructose glucose hfcs metabolism
wise practice of chinese hemodialysis (wishes)

Conditions: Haemolyses and Related Conditions

Summary: the investigators are registering all hd patients at recruited hospitals and developing a hd database in china. patients will be follow-up every 3 months, and both baseline and follow-up information will be entered into the registration system. the patient survival, technical survival, patency rate of access, quality of life and residual renal function for hd patients will be compared using the hd database.

the investigators are registering all end stage renal disease (esrd) patients receiving hemodialysis (hd) treatment, and developing a hd database in china. patients' demographic characteristics (including age, gender, height, weight, bmi, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of esrd, and lab measurements of serum, urine, and access patency), complications, drug information and scores of quality of life at the baseline will be collected. patients will be follow-up every 3 month, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. the investigators also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), technical survival, kidney transplantation, transfer to peritoneal dialysis, hospitalization, access failure，etc. the patient survival, technical survival, patency rate of access, quality of life and residual renal function for hd patients will be compared using the hd database.

Eligibility criteria:
inclusion criteria: end stage renal disease patients receiving hemodialysis treatment. exclusion criteria: no

Keywords: hemodialysis patient survival quality of life hemodialysis access
ckd-330 drug-drug interaction study (candesartan)

Conditions: Hypertension

Summary: the purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of candesartan between free combination of candesartan and amlodipine and candesartan monotherapy.


Eligibility criteria:
inclusion criteria: 1. healthy male volunteer is between 20 and 45 years of age(inclusive) at the pre-study(screening). 2. volunteer who has 19kg/m² ≤ bmi(body mass index) ≤ 26kg/m² 3. when volunteer in screening, must include under the items. 1. 100 mmhg ≤ sitting sbp \<140 mmhg 2. 60 mmhg ≤ sitting dbp \< 90 mmhg 3. 45 bpm ≤ pulse \< 95 bpm 4. those who decided to join the clinical trials by themselves and to comply with the precautions written consent. exclusion criteria: 1. a previous history or present of clinically significant liver, renal, gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, cardiovascular disease. 2. have a gastrointestinal disease history that can affect drug absorption(crohn's disease, ulcers, gerd, gastritis, etc.) or surgery (except simple appendectomy or hernia surgery). 3. the history of clinically significant hypersensitivity reaction about investigational drugs and foods. 4. the history of drug abuse or drug abuse showed a positive for urine drug test. 5. taking drugs have received any other investigational drug within 90 days prior to the first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within 30 days prior to the first dosing. 6. whole blood donation within 60 days prior to the first dosing or plasma donation within 30 days prior to the first dosing. 7. taking drugs that clinical trials expected to affect within 14days or taking food containing caffeine, grapefruit within 7days before the first dosing. 8. a heavy alcohol consumer(alcohol\>3cup/day or 3times/week within last 1month) 9. a heavy smoker(cigarette\>10cigarettes/day) 10. the subject has positive results of serum tests(hepatitis b, c, hiv test, syphilis). 11. have the liver enzyme levels(ast, alt) or bilirubin, total results greater than 1.5 times the unl. 12. have the result of creatinine clearance is less than 80ml/min(cockcroft-gault equation applicable). 13. the result of 12-lead ecg in screening test is qtc\>450msec. 14. an impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
clinical sensitivity verification study of circulating tumor cells gene mutation detection from advanced nsclc patients

Conditions: Advanced NSCLC; Circulating Tumor Cells; Circulating Tumor DNA

Summary: verify the coincidence rate between circulating tumor cells (ctcs) and tumor tissue or circulating tumor dna (ctdna) of advanced nsclc patients with driver gene mutation

1. enrich ctcs from advanced non-small cell lung cancer (nsclc) patients with driver gene mutation, and detect the epidermal growth factor receptor (egfr) mutation, anaplastic lymphoma kinase (alk) fusion, ros proto-oncogene receptor tyrosine kinase 1 (ros1) fusion, ret proto-oncogene (ret) fusion and mesenchymal-epithelial transition factor (met) 14 exon skipping by lung cancer polymerase chain reaction (pcr) panel kit, and verify the mutation coincidence rate between ctcs and tumor tissue. 2. enrich ctdna from advanced nsclc patients with driver gene mutation, detect the egfr mutation by pcr, and detect the alk fusion, ros1 fusion, ret fusion and met 14 exon skipping by next generation sequencing (ngs), and compare the mutation coincidence rate between ctcs and ctdna.

Eligibility criteria:
inclusion criteria: 1. female or male, 18 years of age or older 2. histologically or cytologically proven diagnosis of advanced nsclc patients without any target therapy or chemotherapy 3. able to get tumor tissue gene (egfr/alk/ros1/ret/met skipping) testing results by lung cancer polymerase chain reaction (pcr) panel kit carried out in hospital 4. signed and dated informed consent exclusion criteria: 1. combine with other tumor type 2. the investigator judges the situation that may affect the clinical search process and results
this three-year observational study involves patients of all ages undergoing endovascular treatment for various cerebral or spinal vascular conditions. it aims to assess pre- and post-operative clinical conditions, report complications, and identify preoperative indicators of treatment outcomes. pat

Conditions: Aneurysm Cerebral; AVM; DAFV; ESDC

Summary: this three-year observational study involves patients of all ages undergoing endovascular treatment for various cerebral or spinal vascular conditions. it aims to assess pre- and post-operative clinical conditions, report complications, and identify preoperative indicators of treatment outcomes. patients will also receive psychological support and neuropsychological assessment. clinical, medical, and demographic data will be recorded in a database during hospitalization and follow-up visits.


Eligibility criteria:
inclusion criteria: * patients of both sexes and any age, who are referred to the department of neurosurgery and clinical neurosciences and are candidates for interventional endovascular procedures for any cerebral or spinal pathology, will be included in the study. exclusion criteria: * /

Keywords: endovascular treatment neurospychological assessment aneurysm avm psychological outcome